GlassScriptPhysician profile
Kateryna Markova
NPI 1255688560
$3,274.48
in general payments reported to CMS, 2019-2025
31 companies · $642 in 2025
The $642 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,456 · 2020: $408 · 2021: $119 · 2023: $331 · 2024: $320 · 2025: $642.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,292.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,292.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $365.75 | 2019-2020 | |
| Abbott Laboratories | $326.18 | 2020-2025 | Freestyle Libre 3 |
| Tandem Diabetes Care, INC. | $213.88 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Novo Nordisk INC | $205.31 | 2019-2025 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $197.18 | 2019-2021 | |
| Medtronic, INC. | $177.94 | 2023 | Minimed 780g |
| Dexcom, INC. | $158.87 | 2019-2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $145.44 | 2025 | Recorlev |
| Beta Bionics, INC. | $138.92 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Bayer Healthcare Pharmaceuticals INC. | $130.06 | 2023 | |
| Lilly USA, LLC | $119.38 | 2019-2020 | |
| Abbvie INC. | $118.24 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $112.26 | 2019-2020 | |
| Sequel Med Tech, LLC | $103.88 | 2025 | Twiist |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.97 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $97.68 | 2024-2025 | |
| Amarin Pharma, INC. | $79.27 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $62.20 | 2019-2020 | |
| Ascensia Diabetes Care US INC. | $55.41 | 2019-2023 | |
| Antares Pharma, INC. | $54.70 | 2024-2025 | Xyosted |
| Medtronic Minimed, INC. | $47.23 | 2019 | |
| Merck Sharp & Dohme LLC | $46.74 | 2019 | |
| Eisai INC. | $41.91 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $38.25 | 2019 | |
| Cequr Corporation | $25.74 | 2024 | Cequr Simplicity |
| Corcept Therapeutics | $22.65 | 2019 | |
| Shire North American Group INC | $19.24 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $18.95 | 2019 | |
| Mannkind Corporation | $17.55 | 2019 | |
| Becton, Dickinson and Company | $16.49 | 2019 | |
| Insulet Corporation | $14.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kateryna Markova listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.